Cargando…
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
Immune response to two SARS-CoV-2 mRNA vaccine doses among kidney transplant recipients (KTRs) is limited. We aimed to evaluate humoral and cellular response to a third BNT162b2 dose. In this prospective study, 190 KTRs were evaluated before and ∼3 weeks after the third vaccine dose. The primary out...
Autores principales: | Yahav, Dafna, Rahamimov, Ruth, Mashraki, Tiki, Ben-Dor, Naomi, Steinmetz, Tali, Agur, Timna, Zingerman, Boris, Herman-Edelstein, Michal, Lichtenberg, Shelly, Ben-Zvi, Haim, Bar-Haim, Erez, Cohen, Hila, Rotem, Shahar, Elia, Uri, Margalit, Ili, Zvi, Benaya Rozen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068869/ https://www.ncbi.nlm.nih.gov/pubmed/35529596 http://dx.doi.org/10.3389/ti.2022.10204 |
Ejemplares similares
-
SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
por: Yelin, Dana, et al.
Publicado: (2022) -
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
por: Rozen-Zvi, Benaya, et al.
Publicado: (2021) -
Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022) -
Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
por: Yahav, Dafna, et al.
Publicado: (2021) -
BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)